phosphodiesterase 5 inhibitor

(redirected from PDE5)
Also found in: Acronyms.

phosphodiesterase 5 inhibitor

member of a family of phosphodiesterase inhibitors. Specifically, cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5, which breaks down cGMP and terminates its action. This is the site of action of sildenafil and similar drugs used in the treatment of erectile dysfunction.
See also: sildenafil.
Synonym(s): PDE5
Farlex Partner Medical Dictionary © Farlex 2012
References in periodicals archive ?
"Over the years there have been a number of studies showing overall improvement in the ability to get erections, either alone or with a PDE5 inhibitor."
Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.
To further confirm the above findings, we used zaprinast, a specific inhibitor of phosphodiesterase type 5 (PDE5), to inhibit cGMP hydrolysis and to observe the subsequent effects on PPAR[gamma] and PI3K/AKT signaling on hypoxia-induced HSC activation.
Rosignolo et al., "PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells," Endocrine, vol.
Wessells: PDE5 agents work well in ED in men with diabetes, but we don't know if they work well enough to return men with ED to "normal."
Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities.
We conducted a prospective study of transient evoked otoacoustic emissions (TEOAEs) and distortion-product otoacoustic emissions (DPOAEs) in men who were taking an oral phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction.
If changing the antidepressant dose or addition of a different agent is not a consideration, the use of a phosphodiesterase type-5 (PDE5) inhibitor is effective in improving sexual functioning.
Amac: Spesifik bir fosfodiesteraz-5 (PDE5) inhibitoru olan tadalafilin iyibilinen vazoaktif etkilerinin yani sira antioksidan etkileri de gosterilmistir.
In addition, there are several medical options for the reduction of HAPE incidents: the phosphodiesterase type 5 (PDE5) inhibitor tadalafil (10 mg twice daily [BID]) and dexamethasone (8 mg BID) have been well evaluated [106] as has slow-release nifedipine (30 mg BID) [9].
Increased activity of PDEs has been implicated in a number of clinical conditions including erectile dysfunction (PDE5), cardiovascular diseases (PDEs 3, 4, and 5), pulmonary inflammatory conditions (PDE4), autoimmune diseases (PDEs 3 4, 5, and 7), and cognition and memory disorders (PDEs 1, 2, 3, 4, 7, 9, and 10 A) [5-7].
In addition, a recent study showed the beneficial action of DMC in pulmonary hypertension by inhibiting the PDE5 [10].